GURUFOCUS.COM » STOCK LIST » Consumer Cyclical » Personal Services » Medifast Inc (NYSE:MED) » Definitions » Cash Flow from Financing

Medifast (Medifast) Cash Flow from Financing

: $-80 Mil (TTM As of Dec. 2023)
View and export this data going back to 1981. Start your Free Trial

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Dec. 2023, Medifast paid $0 Mil more to buy back shares than it received from issuing new shares. It received $0 Mil from issuing more debt. It paid $0 Mil more to buy back preferred shares than it received from issuing preferred shares. It spent $18 Mil paying cash dividends to shareholders. It received $0 Mil on other financial activities. In all, Medifast spent $18 Mil on financial activities for the three months ended in Dec. 2023.


Medifast Cash Flow from Financing Historical Data

The historical data trend for Medifast's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medifast Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -82.32 -57.14 -125.13 -199.58 -79.79

Medifast Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Financing Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -24.33 -25.90 -17.84 -18.15 -17.91

Medifast Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Medifast's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

Medifast's Cash from Financing for the quarter that ended in Dec. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-80 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medifast  (NYSE:MED) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Medifast's issuance of stock for the three months ended in Dec. 2023 was $0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Medifast's repurchase of stock for the three months ended in Dec. 2023 was $-0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Medifast's net issuance of debt for the three months ended in Dec. 2023 was $0 Mil. Medifast received $0 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Medifast's net issuance of preferred for the three months ended in Dec. 2023 was $0 Mil. Medifast paid $0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Medifast's cash flow for dividends for the three months ended in Dec. 2023 was $-18 Mil. Medifast spent $18 Mil paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Medifast's other financing for the three months ended in Dec. 2023 was $0 Mil. Medifast received $0 Mil on other financial activities.


Medifast Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Medifast's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Medifast (Medifast) Business Description

Traded in Other Exchanges
Address
100 International Drive, Baltimore, MD, USA, 21202
Medifast Inc is a United states based company that produces, distributes and sells products concerning weight loss, weight management, and healthy living. The company generates its revenue from point of sale transactions executed over an e-commerce platform for weight loss, weight management, and other consumable health and nutritional products.
Executives
Jeffrey J Brown director 19900 MACARTHUR BLVD, SUITE 570, IRVINE CA 92612
Andrea B Thomas director C/O MEDIFAST, INC., 100 INTERNATIONAL DRIVE, BALTIMORE MD 21202
Michael A. Hoer director MEDIFAST, INC., 100 INTERNATIONAL DRIVE, 18TH FLOOR, BALTIMORE MD 21202
Scott Schlackman director 3600 CRONDALL LANE, OWINGS MILLS MD 21117
Hallquist Constance J. director 3600 CRONDALL LANE, OWINGS MILLS MD 21117
Elizabeth A. Geary director C/O MEDIFAST, INC., 100 INTERNATIONAL DRIVE, BALTIMORE MD 21202
Daniel R Chard director, officer: Chief Executive Officer NU SKIN ENTERPRISES, INC., 75 WEST CENTER STREET, PROVO UT 84601
Jonathan Barrett Mackenzie officer: VP, Finance & CAO 100 INTERNATIONAL DRIVE, BALTIMORE MD 21202
Kevin G Byrnes director C/O MEDIFAST, INC., 3600 CRONDALL LANE, OWINGS MILLS MD 21117
Michael C Macdonald director C/O MEDIFAST, INC., 3600 CRONDALL LANE, OWINGS MILLS MD 21117
James P. Maloney officer: Chief Financial Officer 415 HOLIDAY DRIVE, PITTSBURGH PA 15220
Ming Xian director MEDIFAST, INC., 100 INTERNATIONAL DRIVE, 18TH FLOOR, BALTIMORE MD 21202
Carl E Sassano director C/O MEDIFAST, INC., 3600 CRONDALL LANE, OWINGS MILLS MD 21117
Joseph P Kelleman officer: (Interim) CFO 3600 CRONDALL LANE, OWINGS MILLS MD 21117
Timothy G Robinson officer: Chief Financial Officer C/O MEDIFAST, INC., 3600 CRONDALL LANE, OWINGS MILLS MD 21117